News: MediGene AG (MDGGn.DE)

MDGGn.DE on Xetra

3.49EUR
10:49am EST
Price Change (% chg)

€-0.05 (-1.41%)
Prev Close
€3.54
Open
€3.59
Day's High
€3.59
Day's Low
€3.44
Volume
211,461
Avg. Vol
229,993
52-wk High
€5.50
52-wk Low
€3.23

view news for:
Select another date:

Tue, Dec 15 2009

UPDATE 1-MediGene resists any licensing ahead cancer trial data

FRANKFURT, Dec 15 (Reuters) - German biotech firm MediGene said it would likely hold out for more study data on its experimental cancer drug EndoTAG-1, a potential blockbuster, before signing a long awaited deal with a larger partner.

Continue Reading

STOCKS NEWS EUROPE-Medigene seen down, delays drug test

Shares in Medigene are indicated 7.1 percent lower in pre-bourse trade after the biotech company says it will delay testing one of its key drugs in development.

TABLE-MediGene AG 3rd quarter results

Nov 13 (Reuters) - 3 months to 30 Sep 2009 Group (in EUR millions unless otherwise stated)

German stocks - Factors to watch on November 13

FRANKFURT, Nov 13 (Reuters) - The following are some of the factors that may move German stocks on Friday:

STOCKS NEWS EUROPE-MediGene gains as patent granted

Shares in MediGene are up 4 percent to 5.149 euros, making them the strongest performers among German tech stocks , after the antibody specialist biotech company says its has received a patent for the manufacturing process of its lead cancer drug, which is in development.

STOCKS NEWS EUROPE-Medigene gains on drug approval

Shares in German drugmaker Medigene rise as much as 6.9 percent on news its genital wart drug Veregen has won approval in Germany. [ID:nHUGBXFTMa]

STOCKS NEWS EUROPE-Medigene falls as Q2 figs disappoint

Shares in Medigene fall 5.3 percent, making them the sharpest decliners among German tech stocks , after the bitoech reports a larger-than-expected second-quarter loss. DZ Bank analyst Elmar Kraus says Medigene's revenues of 8.4 million euros ($12.06 million) were lower than his broker's estimates of 9.2 million euros and its net loss of 6.37 million euros was below market expectations of 4 million euros.

TABLE-MediGene AG 2nd quarter results

Aug 07 (Reuters) - 3 months to 30 Jun 2009 Group (in EUR millions unless otherwise stated)

STOCKS NEWS EUROPE-Medigene up, drug gets orphan status

Shares in Medigene rise 5.4 percent, making it the top gainer among German tech stocks after the biotech's drug Endotag has been granted Orphan drug status by the U.S. FDA for treatment of pancreatic cancer. "The move was perhaps in the cards, as the drug has orphan status in the EU, but receiving approval hadn't featured in the company's discussions recently," says a London-based analyst.

Pfizer's chances to get MediGene drug grow-sources

FRANKFURT, May 11 (Reuters) - The chances for Pfizer to win a licensing deal for MediGene's promising cancer drug EndoTAG-1 have improved after the German biotech company appointed a new chief executive, two people familiar with the matter told Reuters on Monday.

Select another date:

Market Views

» More MDGGn.DE Market Views

Press Releases

view news for: